Search in:

Advanced search

Expert Opinion on Drug Safety Volume 7, 2008 - Issue 5

Submit an article Journal homepage

437

Views

CrossRef citations to date

Altmetric

Drug Safety Evaluation

Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues

Renato Caviglia Department of Digestive Diseases, Campus Bio-Medico University, Via Alvaro Del Portillo, 200, 00100 Roma, Italy +39 06 225411254; [email protected]

, MD PhD,

Ivo Boškoski Department of Digestive Diseases, Campus Bio-Medico University, Via Alvaro Del Portillo, 200, 00100 Roma, Italy +39 06 225411254; [email protected]

, MD &

Michele Cicala Department of Digestive Diseases, Campus Bio-Medico University, Via Alvaro Del Portillo, 200, 00100 Roma, Italy +39 06 225411254; [email protected]

, MD PhD

Pages 617-632 | Published online: 01 Sep 2008

Cite this article
https://doi.org/10.1517/14740338.7.5.617

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325:1008-16
PubMed Web of Science ®Google Scholar
Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am 2003;31:1-20
Web of Science ®Google Scholar
Lichtenstein GR, Yan S, Bala M, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol 2004;99:91-6
PubMed Web of Science ®Google Scholar
Schreiber S. Medical treatment: an overview. In: Satsangi J, Inflammatory bowel disease. Churchill Livingstone, London: Elsevier Limited; 2003. p. 297-301
Google Scholar
Hanauer S, Sandborn WJ; and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43
PubMed Web of Science ®Google Scholar
Faubion WA Jr, Loftus EV Jr, Harmsen WS, et al. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-60
PubMed Web of Science ®Google Scholar
Korzenik JR. Is Crohn's disease due to defective immunity? Gut 2007;56:2-5
PubMed Web of Science ®Google Scholar
Cario E, Podolsky DK. Intestinal epithelial TOLLerance versus inTOLLerance of commensals. Mol Immunol 2005;42(8):42-9
Google Scholar
Garrett WS, Lord GM, Punit S, et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell 2007;131:33-45
PubMed Web of Science ®Google Scholar
Hecht GA. Inflammatory bowel disease-live transmission. N Engl J Med 2008;358(5):528-30
PubMed Web of Science ®Google Scholar
Hanauer S. Efficacy and safety of tumour necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies [review]. Rev Gastroenterol Disord 2004;4(Suppl 3):S18-24
PubMedGoogle Scholar
Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? [review]. Semin Arthritis Rheum 2005;34(Suppl 1):12-8
PubMed Web of Science ®Google Scholar
Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995;7:251-9
PubMed Web of Science ®Google Scholar
Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease [review]. Gastroenterology 2006;130(3):940-87
PubMed Web of Science ®Google Scholar
Nesbitt A, Fossati G, Bergin M, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other antitumour necrosis factor alpha agents. Inflamm Bowel Dis 2007;13(11):1323-32
PubMed Web of Science ®Google Scholar
Reddy JG, Loftus E Jr. Safety of in fliximab and other biologic agents in the inflammatory bowel diseases. Gastroenterol Clin North Am 2006;35(4):837-55
PubMed Web of Science ®Google Scholar
Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab [review]. Clin Pharmacokinet 2007;46(8):645-60
PubMed Web of Science ®Google Scholar
Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with antitumour necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003;125(1):32-9
PubMed Web of Science ®Google Scholar
Periodic Safety Update Reports. (PSUR 16, October 2007;PSUR 17, April 2008)
Google Scholar
Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86
PubMed Web of Science ®Google Scholar
Dixon WG, Watson K, Lunt M, et al.; British Society for Rheumatology Biologics Register. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006;54(8):2368-76
PubMed Web of Science ®Google Scholar
Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo Clinic experience in 500 patients. Gastroenterology 2004;126:19-31
PubMed Web of Science ®Google Scholar
Caviglia R, Ribolsi M, Rizzi M, et al. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J Gastroenterol 2007;13(39):5238-44
PubMed Web of Science ®Google Scholar
Lichtenstein GR, Feagan BG, Cohen R, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006;4:621-30
PubMed Web of Science ®Google Scholar
Colombel JF, D'Haens G, Rutgeerts P, et al. No new safety signals identified in Crohn's disease patients treated with infliximab in an interim review of the ENCORE registry [abstract]. Gastroenterology 2008;134:A-472 [T1048]
Google Scholar
Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-36
PubMed Web of Science ®Google Scholar
Lavagna A, Bergallo M, Daperno M, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007;13(7):896-902
PubMed Web of Science ®Google Scholar
Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. J Rheumatol 2003;30:1624-5
PubMed Web of Science ®Google Scholar
Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis 2003;62:686-7
PubMed Web of Science ®Google Scholar
Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004;53:1363-5
PubMed Web of Science ®Google Scholar
Oniankitan O, Duvoux C, Challine D, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004;31:107-9
PubMed Web of Science ®Google Scholar
Ehlers S. Tumour necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 2005;41:S199-203
PubMed Web of Science ®Google Scholar
Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;169:4620-7
PubMed Web of Science ®Google Scholar
Theis VS, Rhodes JM. Review article: minimizing tuberculosis during antitumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27(1):19-30
PubMed Web of Science ®Google Scholar
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumour necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
PubMed Web of Science ®Google Scholar
Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7
PubMed Web of Science ®Google Scholar
Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9
PubMed Web of Science ®Google Scholar
Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials [review]. JAMA 2006;295(19):2275-85
PubMed Web of Science ®Google Scholar
Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of TB in rheumatoid arthritis associated with tumour necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92
PubMed Web of Science ®Google Scholar
Remicade (infliximab) for IV injection [prescribing information]. Malvern, PA. Centocor; 2006
Google Scholar
Centers for Disease Control and Prevention. Tuberculosis associated with blocking agents against tumour necrosis factor-alpha, California, 2002 – 2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6
Google Scholar
Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent TB infection. Can Med Assoc J 2003;168:1153-6
PubMed Web of Science ®Google Scholar
Vlachaki E, Psathakis K, Tsintiris K, et al. Delayed response to anti-TB treatment in a patient on infliximab. Respir Med 2005;99:648-52
PubMed Web of Science ®Google Scholar
Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8
PubMed Web of Science ®Google Scholar
Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53
PubMed Web of Science ®Google Scholar
Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
PubMed Web of Science ®Google Scholar
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76
PubMed Web of Science ®Google Scholar
Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during antitumour necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001;44(12):2862-9
PubMed Web of Science ®Google Scholar
Thomas CW Jr, Weinshenker BG, Sandborn WJ. Demyelination during antitumour necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004;10:28-31
PubMed Web of Science ®Google Scholar
Andersen N, Caspersen S, Peterse N. Crohn disease and demyelinating. The National Danish Crohn's colitis infliximab database 1999 – 2005 [abstract]. Gut 2006;55(Suppl V):A109
Google Scholar
Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005;129:819-26
PubMed Web of Science ®Google Scholar
Biancone L, Orlando A, Kohn A, et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multi-centre matched pair study. Gut 2006;55:228-33
PubMed Web of Science ®Google Scholar
Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105(6):1716-23
PubMed Web of Science ®Google Scholar
Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350:876-85
PubMed Web of Science ®Google Scholar
Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62
PubMed Web of Science ®Google Scholar
Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914-21
PubMed Web of Science ®Google Scholar
Gyde SN, Prior P, MacArtney JC, et al. Malignancy in Crohn's disease. Gut 1980;21:1024-9
PubMed Web of Science ®Google Scholar
Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004;53:849-53
PubMed Web of Science ®Google Scholar
Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukaemia 2000;14:991-7
PubMed Web of Science ®Google Scholar
Belhadj K, Reyes F, Farcewt J-P, et al. Hepatosplenic T cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 2003;102:4261-9
PubMed Web of Science ®Google Scholar
Cooke C, Krenacs L, Steltler-Stevenson M, et al. Hepatosplenic T cell lymphoma: a distinct clinicopathologic entity of cytotoxic gamma delta origin. Blood 1996;88:4265-74
PubMed Web of Science ®Google Scholar
Navarro JT, Ribera JM, Mate JL, et al. Hepatosplenic T-gamma delta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk Lymphoma 2003;44:531-3
PubMed Web of Science ®Google Scholar
Mahadevan U. Continuing immunomodulators and biologic medications in pregnant IBD patients-pro. Inflamm Bowel Dis 2007;13(11):1439-40
PubMed Web of Science ®Google Scholar
Cornish J, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy [review]. Gut 2007;56(6):830-7
PubMed Web of Science ®Google Scholar
Mahadevan U, Sandborn WJ, Li DK, et al. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007;133(4):1106-12
PubMed Web of Science ®Google Scholar
Alstead EM, Nelson-Piercy C. Inflammatory bowel disease in pregnancy. Gut 2003;52(2):159-161
PubMed Web of Science ®Google Scholar
Remicade product information. In: Physicians desk reference. 58th edition. Montvale, NJ: Medical Economics Company, Inc.; 2004. p. 1145-8
Google Scholar
Mahadevan U, Kane S, Sandborn WJ, et al. Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005;21:733-8
PubMed Web of Science ®Google Scholar
Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006;4(10):1255-8
PubMed Web of Science ®Google Scholar
Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004;99(12):2385-92
PubMed Web of Science ®Google Scholar
Mahadevan U, Kane SV, Church JA. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008;134(Suppl 1):A-69
Google Scholar
Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engl J Med 1990;323:236-41
PubMed Web of Science ®Google Scholar
Yokoyama T, Vaca L, Rossen RD, et al. Cellular basis for the negative inotropic effects of tumour necrosis factor-α in the adult mammalian heart. J Clin Invest 1993;92:2303-12
PubMed Web of Science ®Google Scholar
Krown KA, Page MT, Nguyen C, et al. Tumour necrosis factor α-induced apoptosis in cardiac myocytes: involvement of the sphingolipid signalling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65
PubMed Web of Science ®Google Scholar
Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumour necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003;107:3133-40
PubMed Web of Science ®Google Scholar
Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumour necrosis factor antagonist. Ann Intern Med 2003;138:807-11
PubMed Web of Science ®Google Scholar
Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001;76:84-6
PubMed Web of Science ®Google Scholar
Foeldvari I, Kruger E, Schneider T. Acute, non-obstructive, sterile cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis. Ann Rheum Dis 2003;62:908-9
PubMed Web of Science ®Google Scholar
Hyams J, Crandall W, Kugathasan S, et al. REACH Study Group. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132(3):863-73
PubMed Web of Science ®Google Scholar
Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999;340(18):1398-405
PubMed Web of Science ®Google Scholar
Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumour necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337(15):1029-35
PubMed Web of Science ®Google Scholar
Rutgeerts P, D'Haens G, Targan S, et al. Efficacy and safety of retreatment with antitumour necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 1999;117(4):761-9
PubMed Web of Science ®Google Scholar
Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005;128(7):1805-11
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date